Logo image of PALI

PALISADE BIO INC (PALI) Stock Fundamental Analysis

NASDAQ:PALI - Nasdaq - US6963894026 - Common Stock

1.42  -0.09 (-5.96%)

Fundamental Rating

2

Taking everything into account, PALI scores 2 out of 10 in our fundamental rating. PALI was compared to 572 industry peers in the Biotechnology industry. The financial health of PALI is average, but there are quite some concerns on its profitability. PALI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PALI had negative earnings in the past year.
PALI had a negative operating cash flow in the past year.
PALI had negative earnings in each of the past 5 years.
PALI had a negative operating cash flow in each of the past 5 years.
PALI Yearly Net Income VS EBIT VS OCF VS FCFPALI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

With a Return On Assets value of -150.65%, PALI is not doing good in the industry: 84.96% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -212.85%, PALI is doing worse than 69.73% of the companies in the same industry.
Industry RankSector Rank
ROA -150.65%
ROE -212.85%
ROIC N/A
ROA(3y)-130.24%
ROA(5y)-128.45%
ROE(3y)-194.79%
ROE(5y)-182.77%
ROIC(3y)N/A
ROIC(5y)N/A
PALI Yearly ROA, ROE, ROICPALI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PALI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PALI Yearly Profit, Operating, Gross MarginsPALI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50K -100K -150K -200K

More info and screens

5

2. Health

2.1 Basic Checks

PALI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PALI has more shares outstanding
PALI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PALI is higher compared to a year ago.
PALI Yearly Shares OutstandingPALI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K
PALI Yearly Total Debt VS Total AssetsPALI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

PALI has an Altman-Z score of -23.39. This is a bad value and indicates that PALI is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -23.39, PALI is not doing good in the industry: 88.50% of the companies in the same industry are doing better.
There is no outstanding debt for PALI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -23.39
ROIC/WACCN/A
WACC11.05%
PALI Yearly LT Debt VS Equity VS FCFPALI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

PALI has a Current Ratio of 3.31. This indicates that PALI is financially healthy and has no problem in meeting its short term obligations.
PALI's Current ratio of 3.31 is on the low side compared to the rest of the industry. PALI is outperformed by 60.71% of its industry peers.
PALI has a Quick Ratio of 3.31. This indicates that PALI is financially healthy and has no problem in meeting its short term obligations.
PALI has a Quick ratio (3.31) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.31
Quick Ratio 3.31
PALI Yearly Current Assets VS Current LiabilitesPALI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

PALI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -122.42%.
Looking at the last year, PALI shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
The Revenue has been decreasing by -0.78% on average over the past years.
EPS 1Y (TTM)-122.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.85%
Revenue 1Y (TTM)-100%
Revenue growth 3Y164.57%
Revenue growth 5Y-0.78%
Sales Q2Q%N/A

3.2 Future

PALI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.41% yearly.
PALI is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y56.71%
EPS Next 2Y36.62%
EPS Next 3Y23.19%
EPS Next 5Y12.41%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PALI Yearly Revenue VS EstimatesPALI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M
PALI Yearly EPS VS EstimatesPALI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -100K -200K -300K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PALI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PALI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PALI Price Earnings VS Forward Price EarningsPALI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PALI Per share dataPALI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

PALI's earnings are expected to grow with 23.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.62%
EPS Next 3Y23.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PALI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PALISADE BIO INC

NASDAQ:PALI (1/22/2025, 11:37:43 AM)

1.42

-0.09 (-5.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners2.89%
Inst Owner Change0%
Ins Owners1.81%
Ins Owner Change0.04%
Market Cap3.93M
Analysts84.44
Price Target30.94 (2078.87%)
Short Float %2.42%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.51%
Min EPS beat(2)-11.13%
Max EPS beat(2)32.15%
EPS beat(4)2
Avg EPS beat(4)1.27%
Min EPS beat(4)-22.19%
Max EPS beat(4)32.15%
EPS beat(8)4
Avg EPS beat(8)46.02%
EPS beat(12)8
Avg EPS beat(12)46.78%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2600%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 0.6
EV/EBITDA N/A
EPS(TTM)-16.68
EYN/A
EPS(NY)-3.89
Fwd EYN/A
FCF(TTM)-4.53
FCFYN/A
OCF(TTM)-4.53
OCFYN/A
SpS0
BVpS2.39
TBVpS2.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -150.65%
ROE -212.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-130.24%
ROA(5y)-128.45%
ROE(3y)-194.79%
ROE(5y)-182.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.31
Quick Ratio 3.31
Altman-Z -23.39
F-Score2
WACC11.05%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-122.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.85%
EPS Next Y56.71%
EPS Next 2Y36.62%
EPS Next 3Y23.19%
EPS Next 5Y12.41%
Revenue 1Y (TTM)-100%
Revenue growth 3Y164.57%
Revenue growth 5Y-0.78%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-10.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.2%
OCF growth 3YN/A
OCF growth 5YN/A